Aziridinyl Dimeric Naphthoquinones Overcome AML Drug Resistance
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) are inadequate due to drug resistance and limited therapeutic options, with chemotherapy being the mainstay of therapy for over 40 years, and existing quinone-based anticancer agents facing challenges in overcoming resistance in malignant cells.
Innovation Solution
Development of aziridinyl and other amino dimeric naphthoquinones that induce oxidative stress, damage DNA, and interact with cellular proteins, offering triple modes of action against AML cells, including compounds like Compound 101 and 102, which are designed to enhance solubility and cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used as the mainstay of therapy for AML, then remission of the disease can be attempted, but treatment outcomes remain unsatisfactory with limited survival rates and drug resistance develops
Solution Approach 1:
The patent applies composite materials by combining a naphthoquinone core structure with an aziridine moiety to create a hybrid molecule (Compound 101) that integrates the oxidative stress-inducing capability of quinones with the DNA-alkylating power of aziridines. This composite structure enables dual mechanisms of action that overcome drug resistance while maintaining therapeutic effectiveness against AML cells
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of conventional naphthoquinone compounds through the addition of an aziridine group at the 2-position. This structural parameter change transforms the compound's biological properties, enabling it to induce both oxidative stress and DNA damage, thereby achieving 10-fold increased potency and overcoming resistance to traditional chemotherapy agents
2Reliability
If new therapeutic agents are developed to overcome drug resistance, then treatment potency can be increased, but the complexity of the compounds increases
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic function into two distinct modules: the naphthoquinone core that generates oxidative stress and the aziridine group that alkylates DNA. This segmentation allows each component to perform its specific function independently while working synergistically, achieving high potency without excessive molecular complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate up to 10-fold increased potency in cell proliferation assays and effectively inhibit AML cell lines and primary cells, showing potential in overcoming drug resistance and improving treatment outcomes for AML.
Implementation Method 1
Dimeric naphthoquinones kill AML cells by induction of oxidative stress
Implementation Method 2
damaging DNA
Implementation Method 3
interacting with cellular proteins involves in oxidative response
Implementation Method 4
disrupting mitochondrial membrane potential
Data Source
AI summary
The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.